CDK6-CCND1 Heterodimer Protein, Human (Sf9)

The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (Sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by Sf9 insect cells , with tag free.

The CDK6ic complex, a serine/threonine-protein kinase, assumes a pivotal role in cell cycle regulation and differentiation, specifically promoting the G1/S transition. This complex exerts its regulatory influence by phosphorylating critical substrates such as pRB/RB1 and NPM1. During interphase, the CDK6 interacts with D-type G1 cyclins, forming an active pRB/RB1 kinase and governing entry into the cell cycle. Notably, this complex is intricately involved in both the initiation and maintenance of cell cycle exit during cellular differentiation, acting as a negative regulator of cell differentiation while remaining essential for the proliferation of specific cell types, including erythroid and hematopoietic cells. Its indispensable role extends to thymocyte development and the promotion of newborn neuron production. Furthermore, in astrocytes, the CDK6-CCND1 complex facilitates changes in gene expression patterns, modulates the actin cytoskeleton, and enhances motility during cell differentiation. Importantly, it exerts regulatory control over myeloid differentiation and delays senescence, highlighting its diverse and crucial functions in cellular processes. Additionally, the complex plays a role in promoting beta-cell proliferation in the pancreatic islets of Langerhans and may contribute to centrosome organization during various cell cycle phases.

Human

Sf9 insect cells

Tag Free

Q00534 (M1-A326)&P24385 (M1-I295)

1021&595

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.